NCT02333565View on ClinicalTrials.gov

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

January 21, 2019

Study Completion Date

May 24, 2023

Conditions
Recurrent MeningiomasResistant Meningiomas
Interventions
DRUG

Everolimus

DRUG

Octreotide

Trial Locations (1)

13354

Assistance Publique Hôpitaux Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT02333565 - Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas | Biotech Hunter | Biotech Hunter